Mustang driven up as it updates on its CAR-T cell therapy portfolio

Clinical-stage US biotech Mustang Biotech (Nasdaq: MBIO), which is focused on cell and gene therapies for hematologic cancers, solid tumors and rare genetic diseases, today provided updates on its CAR-T portfolio and 2023 anticipated milestones. The firm’s shares advanced 5.8% to $0.37 following the announcement.

Following lackluster allogeneic CAR-T data presented by multiple companies at ASH, Mustang’s lead clinical candidate, MB-106, has a competitive edge in a  market estimated to reach $2.79B by 2030, the company noted.

The CD20-targeted, first-in-class autologous CAR-T cell therapy being evaluated to treat relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHLs) and chronic lymphocytic leukemia (CLL) has generated compelling interim data that compares favorably to the likes of Yescarta [Gilead Sciences’ axicabtagene ciloleucel], odronextamab [from Regeneron Pharmaceuticals] and mosunetuzumab [Roche’s Lunsumio], said Mustang.